Skip to Content
Søk Menu

ASCO 2019: High-risk prostate cancer: 10 year results after image guided intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relateret indhold

Norwegian Perspectives on Urogenital Cancer at ESMO 2024

/ BestPractice Nordic
BlærekreftESMO24NyresykdomProstatakreft
Gedske Daugaard

Enzalutamide plus Radium223 Treatment as First-Line for mCRPC in a Nordic Perspective

/ Gedske Daugaard
ESMO24Prostatakreft Play the Video 5:55
Silke Gillessen

PEACE-3 study: Enzalutamide and Ra-223 as First-Line Therapy for mCRPC

/ Silke Gillessen
ESMO24Prostatakreft Play the Video 11:05

Androgen Receptor Pathway Inhibitors (ARPIs) Are Superior to Taxanes for Castrate-Resistant Metastatic Prostate Cancer

/ Henrik Grönberg
ESMO24Prostatakreft Play the Video 02:35
Daniel Heinrich

Highlights from ESMO 2024: More Intelligent Choice of Treatment in the Future

/ Daniel Heinrich
BlærekreftESMO24NyrekreftProstatakreft Play the Video 4:25
Fred Saad

Darolutamide May Be an Effective Alternative Treatment Option for mHSPC

/ Fred Saad
ESMO24Prostatakreft Play the Video 3:46

Get in the Perineum! – Refinement of Prostate Biopsy Technique for Patient Safety and Antibiotic Stewardship

/ Lars Boesen
Prostatakreft
Jerome Leow

PSMA PET Staging Significantly Improves Prognosis in Pelvic Node-Positive Prostate Cancer

/ Boon Yang Jerome Leow
Prostatakreft Play the Video 07:19
Thorgerdur Palsdottir

The Capio Model for Prostate Cancer Diagnostics

/ Thorgerdur Palsdottir
ASCO24Prostatakreft Play the Video 8:20
Back to top